TY - JOUR
T1 - A toxicity cost function approach to optimal CPA equilibration in tissues
AU - Benson, James D.
AU - Higgins, Adam Z.
AU - Desai, Kunjan
AU - Eroglu, Ali
N1 - Funding Information:
This work was supported by funding from the Natural Sciences and Engineering Research Council of Canada ( RGPIN-2017-06346 to JB), National Institute of Child Health and Human Development ( 5R01HD083930-02 to JB), and the National Institute of Biomedical Imaging and Bioengineering (Grant No. R21 EB018538 to AE).We thank Dr. Mabel Gamboa, Ms. Mary Anne Park, and personnel of the Augusta University Biorepository for their help with procurement of tissue samples.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - There is growing need for cryopreserved tissue samples that can be used in transplantation and regenerative medicine. While a number of specific tissue types have been successfully cryopreserved, this success is not general, and there is not a uniform approach to cryopreservation of arbitrary tissues. Additionally, while there are a number of long-established approaches towards optimizing cryoprotocols in single cell suspensions, and even plated cell monolayers, computational approaches in tissue cryopreservation have classically been limited to explanatory models. Here we develop a numerical approach to adapt cell-based CPA equilibration damage models for use in a classical tissue mass transport model. To implement this with real-world parameters, we measured CPA diffusivity in three human-sourced tissue types, skin, fibroid and myometrium, yielding propylene glycol diffusivities of 0.6 × 10−6 cm2/s, 1.2 × 10−6 cm2/s and 1.3 × 10−6 cm2/s, respectively. Based on these results, we numerically predict and compare optimal multistep equilibration protocols that minimize the cell-based cumulative toxicity cost function and the damage due to excessive osmotic gradients at the tissue boundary. Our numerical results show that there are fundamental differences between protocols designed to minimize total CPA exposure time in tissues and protocols designed to minimize accumulated CPA toxicity, and that “one size fits all” stepwise approaches are predicted to be more toxic and take considerably longer than needed.
AB - There is growing need for cryopreserved tissue samples that can be used in transplantation and regenerative medicine. While a number of specific tissue types have been successfully cryopreserved, this success is not general, and there is not a uniform approach to cryopreservation of arbitrary tissues. Additionally, while there are a number of long-established approaches towards optimizing cryoprotocols in single cell suspensions, and even plated cell monolayers, computational approaches in tissue cryopreservation have classically been limited to explanatory models. Here we develop a numerical approach to adapt cell-based CPA equilibration damage models for use in a classical tissue mass transport model. To implement this with real-world parameters, we measured CPA diffusivity in three human-sourced tissue types, skin, fibroid and myometrium, yielding propylene glycol diffusivities of 0.6 × 10−6 cm2/s, 1.2 × 10−6 cm2/s and 1.3 × 10−6 cm2/s, respectively. Based on these results, we numerically predict and compare optimal multistep equilibration protocols that minimize the cell-based cumulative toxicity cost function and the damage due to excessive osmotic gradients at the tissue boundary. Our numerical results show that there are fundamental differences between protocols designed to minimize total CPA exposure time in tissues and protocols designed to minimize accumulated CPA toxicity, and that “one size fits all” stepwise approaches are predicted to be more toxic and take considerably longer than needed.
UR - http://www.scopus.com/inward/record.url?scp=85032817090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032817090&partnerID=8YFLogxK
U2 - 10.1016/j.cryobiol.2017.09.005
DO - 10.1016/j.cryobiol.2017.09.005
M3 - Article
C2 - 28966012
AN - SCOPUS:85032817090
SN - 0011-2240
VL - 80
SP - 144
EP - 155
JO - Cryobiology
JF - Cryobiology
ER -